Induced Pluripotent Stem Cell (iPSC) Market Share, Size, Trends, Industry Analysis Report, By Derived Cell (Hepatocytes, Fibroblasts, Amniotic Cells, Cardiomyocytes, Others); By Application; By Region; Segment Forecast, 2023 - 2032

Induced Pluripotent Stem Cell (iPSC) Market Share, Size, Trends, Industry Analysis Report, By Derived Cell (Hepatocytes, Fibroblasts, Amniotic Cells, Cardiomyocytes, Others); By Application; By Region; Segment Forecast, 2023 - 2032

The global induced pluripotent stem cell (iPSC) market size is expected to reach USD 5.37 billion by 2032, according to a new study by Polaris Market Research. The report “Induced Pluripotent Stem Cell (iPSC) Market Share, Size, Trends, Industry Analysis Report, By Derived Cell (Hepatocytes, Fibroblasts, Amniotic Cells, Cardiomyocytes, Others); By Application; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The Induced Pluripotent Stem Cell (iPSC) market refers to the demand for cells reprogrammed from adult cells to a pluripotent state, meaning they can differentiate into various cell types in the body. iPSCs are generated by introducing specific genes or factors into adult cells, typically through genetic reprogramming techniques. These cells can be used in various applications such as disease modeling, drug discovery, regenerative medicine, and personalized therapies.

The iPSC market is driven by factors such as the increasing prevalence of chronic diseases, growing demand for regenerative medicine, advancements in cellular reprogramming technologies, and increasing investments in research and development. iPSCs offer several advantages over other cell types, including their ability to be derived from patient-specific cells, which allows for personalized disease modeling and drug screening. They also have the potential to address limitations associated with using embryonic stem cells, as their generation does not involve the destruction of embryos.

The iPSC market is characterized by various suppliers and research institutions providing iPSC lines, differentiation kits, and related products and services. Additionally, collaborations and partnerships between academic institutions, pharmaceutical companies, and biotechnology firms drive innovation and commercialization of iPSC-based technologies.

The iPSC market is expected to experience significant growth in the coming years, driven by increasing research activities, advancements in genome editing technologies, and the potential for iPSCs to revolutionize personalized medicine and regenerative therapies. However, challenges such as the complexity of reprogramming processes, standardization of iPSC production, and regulatory considerations must be addressed to realize the market's potential fully.

The demand for induced pluripotent stem cells (iPSCs) as research tools has been driven by scientists' continuous efforts to develop new treatments and therapies for managing SARS-CoV-2 infection. iPSCs can generate organ models or organoids that closely mimic human physiology, making them valuable for studying the pathophysiology of the virus.

For instance, in a published article from October 2022, researchers in Japan utilized human induced pluripotent stem cells to create Human Induced Salivary Glands to investigate the role of these glands as reservoirs for the COVID-19 virus. The researchers concluded that hiSGs could serve as a promising in-vitro model for future investigations, enhancing our understanding of the spread of SARS-CoV-2 infection. Consequently, the demand for iPSCs as a powerful research tool will increase.

Induced Pluripotent Stem Cell (iPSC) Market Report Highlights

In 2022, the Cardiomyocytes segment accounted for the largest the induced pluripotent stem cell (iPSC) market share. Cardiomyocytes, specialized heart cells, hold immense potential for regenerative medicine and drug discovery applications. Cardiovascular diseases, such as heart failure and cardiac arrhythmias, are major global health concerns, driving the demand for effective treatments.

In 2022, the Drug development and discovery segment held the fastest-growing market share in the Induced Pluripotent Stem Cell (iPSC) market. The iPSCs offer a unique and valuable platform for studying human disease mechanisms and developing novel therapeutic interventions. These cells can be differentiated into various cell types, including cardiomyocytes, neurons, liver cells, and more, providing researchers with human-relevant models for drug testing.

In 2022, North America accounted for the largest Induced Pluripotent Stem Cells (iPSCs) market. Regulatory bodies such as the Food and Drug Administration (FDA) in the United States have established guidelines and frameworks to facilitate the translation of iPSC research into clinical applications. This regulatory support has encouraged investment and innovation in the iPSC field, further driving the market growth in North America.

The global key market players include Thermo Fisher Scientific Inc., FUJIFILM Holdings Corporation (Cellular Dynamics), Astellas Pharma Inc., Takara Bio Inc, Cynata Therapeutics Limited, Axol Bioscience Ltd., Fate Therapeutics, Ncardia, ViaCyte, Inc., and REPROCELL USA, Inc.

Polaris Market Research has segmented the induced pluripotent stem cell (iPSC) market report based on derived cell, application, and region:

Induced Pluripotent Stem Cell (iPSC), Derived Cell Outlook (Revenue - USD Billion, 2019 - 2032)

Hepatocytes

Fibroblasts

Amniotic Cells

Cardiomyocytes

Others

Induced Pluripotent Stem Cell (iPSC), Application Outlook (Revenue - USD Billion, 2019 - 2032)

Manufacturing

Academic Research

Drug Development & Discovery

Toxicity Screening

Regenerative Medicine

Induced Pluripotent Stem Cell (iPSC), Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa